MA39059A1 - Système d'administration de médicament. - Google Patents

Système d'administration de médicament.

Info

Publication number
MA39059A1
MA39059A1 MA39059A MA39059A MA39059A1 MA 39059 A1 MA39059 A1 MA 39059A1 MA 39059 A MA39059 A MA 39059A MA 39059 A MA39059 A MA 39059A MA 39059 A1 MA39059 A1 MA 39059A1
Authority
MA
Morocco
Prior art keywords
therapeutic agent
thermoplastic polymer
delivery system
drug delivery
core
Prior art date
Application number
MA39059A
Other languages
English (en)
Inventor
Willy J H Verhoeven
Graaff Wouter De
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA39059A1 publication Critical patent/MA39059A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système intravaginal d'administration de médicament comprenant (i) un noyau comprenant un premier polymère thermoplastique et un premier agent thérapeutique, le premier agent thérapeutique étant dissous dans le premier polymère thermoplastique et (ii) une pellicule entourant le noyau comprenant un deuxième polymère thermoplastique, le premier agent thérapeutique étant moins perméable dans le deuxième polymère thermoplastique que dans le premier polymère thermoplastique, et un deuxième agent thérapeutique sous forme solide, le deuxième agent thérapeutique étant chargé dans une partie de la pellicule.
MA39059A 2013-12-11 2014-12-08 Système d'administration de médicament. MA39059A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196737 2013-12-11
PCT/EP2014/076823 WO2015086491A1 (fr) 2013-12-11 2014-12-08 Système d'administration de médicament.

Publications (1)

Publication Number Publication Date
MA39059A1 true MA39059A1 (fr) 2018-08-31

Family

ID=49759119

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39059A MA39059A1 (fr) 2013-12-11 2014-12-08 Système d'administration de médicament.

Country Status (23)

Country Link
US (1) US10413504B2 (fr)
EP (1) EP3079660B1 (fr)
JP (1) JP6251396B2 (fr)
KR (1) KR101808977B1 (fr)
CN (1) CN105979930B (fr)
AP (1) AP2016009223A0 (fr)
AU (1) AU2014363724B2 (fr)
BR (1) BR112016013325B1 (fr)
CA (1) CA2931559C (fr)
CR (1) CR20160261A (fr)
DO (1) DOP2016000132A (fr)
EA (1) EA031802B1 (fr)
HK (1) HK1224208A1 (fr)
IL (1) IL245544A0 (fr)
MA (1) MA39059A1 (fr)
MD (1) MD20160079A2 (fr)
MX (1) MX2016007681A (fr)
PE (1) PE20160680A1 (fr)
PH (1) PH12016501083A1 (fr)
SG (1) SG11201604660VA (fr)
SV (1) SV2016005214A (fr)
TW (1) TW201607563A (fr)
WO (1) WO2015086491A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
JP2016540006A (ja) 2013-12-19 2016-12-22 ザ プロクター アンド ギャンブル カンパニー 還元性組成物及び定着用組成物を使用したケラチン繊維の整形
US11110046B2 (en) 2013-12-19 2021-09-07 The Procter And Gamble Company Shaping keratin fibres using 2-hydroxypropane-1,2,3-tricarboxylic acid and/or 1,2,3,4-butanetetracarboxylic acid
EP3082735B1 (fr) 2013-12-19 2018-05-02 The Procter and Gamble Company Formage de fibres de kératine au moyen d'acide oxo-éthanoïque et/ou de dérivés de celui-ci
JP6334709B2 (ja) 2013-12-19 2018-05-30 ザ プロクター アンド ギャンブル カンパニー カルボネートエステルを使用したケラチン繊維の真直化方法
EP3082733A1 (fr) 2013-12-19 2016-10-26 The Procter & Gamble Company Mise en forme de fibres de kératine à l'aide d'un agent actif comprenant un groupe fonctionnel choisi dans le groupe constitué par : -c(=o)-, -c(=o)-h, et -c(=o)-o-
JP6385438B2 (ja) 2013-12-19 2018-09-05 ザ プロクター アンド ギャンブル カンパニー 糖類を使用したケラチン繊維の成形
MX361102B (es) 2013-12-19 2018-11-27 Procter & Gamble Modelado de fibras de queratina con el uso de un agente activo que comprende al menos dos grupos funcionales seleccionados de: -c(oh)- y -c(=o)oh.
EP3017809A1 (fr) * 2014-11-07 2016-05-11 Ferring B.V. Unité de dispositif de médicaments contenant de la quinagolide
WO2016100257A1 (fr) 2014-12-19 2016-06-23 The Procter & Gamble Company Modelage de fibres de kératine à l'aide d'arabinose et de carbonate d'éthylène
CN107106438A (zh) 2014-12-19 2017-08-29 宝洁公司 成形角蛋白纤维的方法
MX2017016152A (es) 2015-06-18 2018-04-18 Procter & Gamble Modelado de fibras de queratina mediante el uso de compuestos de dialdehido.
JP6878429B2 (ja) * 2015-08-11 2021-05-26 ペーテーテー ホールディング アーペーエスＰｔｔ Ｈｏｌｄｉｎｇ Ａｐｓ 送達デバイス
EP3395335A1 (fr) * 2017-04-24 2018-10-31 Kern Pharma, S.L. Anneau vaginal pour la libération simultanée de deux principes actifs
DE102017113166A1 (de) * 2017-06-14 2018-12-20 Amw Gmbh Depotform zur Abgabe eines Östrogen-Wirkstoffs
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (fr) 2018-05-24 2019-11-28 Nureva Inc. Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones
WO2019226519A1 (fr) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
WO2022231930A1 (fr) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
WO2023141198A1 (fr) * 2022-01-21 2023-07-27 The Population Council, Inc. Anneaux intravaginaux de thérapie combinée
EP4215180A1 (fr) * 2022-01-21 2023-07-26 Sever Pharma Solutions Système d'administration de médicaments
AU2023401287A1 (en) 2022-12-02 2025-06-19 Vari Bioscience Gmbh Estriol vaginal ring

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
DE3571924D1 (en) 1984-04-11 1989-09-07 Thiemann Arzneimittel Gmbh Dosage units for controlled release of active material
EP0180264A1 (fr) 1984-10-12 1986-05-07 Akzo N.V. Système de libération pour deux ou plusieurs substances actives
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
ES2054784T3 (es) 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
US6544546B1 (en) 1995-07-04 2003-04-08 Akzo Nobel, N.V. Ring-shaped devices
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
IL123813A0 (en) * 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
DE69817017T2 (de) 1997-12-12 2004-02-26 Akzo Nobel N.V. Verpackung für einen vaginalring
WO1999031137A1 (fr) 1997-12-18 1999-06-24 Eli Lilly And Company Teriparatide cristalline
US6579533B1 (en) 1999-11-30 2003-06-17 Bioasborbable Concepts, Ltd. Bioabsorbable drug delivery system for local treatment and prevention of infections
CA2442281C (fr) 2001-03-27 2010-06-08 Galen (Chemicals) Limited Dispositifs d'administration de medicament par voie intravaginale destines a l'administration d'agent antimicrobien
CA2451187C (fr) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
CN1289064C (zh) 2001-08-31 2006-12-13 先灵有限责任公司 药物输送体系
CA2447984A1 (fr) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Formes dosifiees presentant un noyau interne et une couche externe de formes differentes
CN1242819C (zh) 2002-06-07 2006-02-22 上海市计划生育科学研究所 一种新型阴道环及制备方法
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
CA2531640C (fr) 2003-07-10 2013-06-18 Galen (Chemicals) Limited Dispositifs d'administration de medicaments par voie intravaginale
PL1670440T3 (pl) * 2003-09-29 2014-11-28 Novo Nordisk Healthcare Ag Preparaty HRT
US8481079B2 (en) * 2004-03-24 2013-07-09 Merck Sharp & Dohme B.V. Drug delivery system based on polyethylene vinylacetate copolymers
KR20060046263A (ko) * 2004-08-04 2006-05-17 도쿄파츠고교 가부시키가이샤 편평형 진동모터를 내장시킨 전자음향변환기
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
US20100136090A1 (en) 2006-11-20 2010-06-03 N.V. Organon; Intervet International B.V. Helically-Shaped Drug Delivery System
EP2111222B1 (fr) 2007-02-12 2018-06-20 Particle Sciences, Inc. Dispositifs de libération contenant des ingrédients pharmaceutiques actifs encapsulés
US20080242650A1 (en) 2007-03-26 2008-10-02 Jean-Louis Thomas Oral contraceptive regimen
EP2207529B1 (fr) 2007-09-07 2014-12-31 Mati Therapeutics Inc. Noyaux de médicament pour une libération soutenue d'agents thérapeutiques
AR066166A1 (es) 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
AU2010274946B2 (en) * 2009-07-21 2013-09-12 The Population Council, Inc. Multi-layered gradient vaginal ring
EP2468750A1 (fr) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Formes polymorphiques de maléate d'asénapine et procédés de préparation
TW201332585A (zh) 2012-02-14 2013-08-16 Chemo Res S L 核鞘藥物遞送裝置
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
CA2931559A1 (fr) 2015-06-18
TW201607563A (zh) 2016-03-01
US20150157561A1 (en) 2015-06-11
MX2016007681A (es) 2016-10-14
DOP2016000132A (es) 2016-07-31
IL245544A0 (en) 2016-06-30
CA2931559C (fr) 2018-03-13
BR112016013325B1 (pt) 2022-11-29
JP6251396B2 (ja) 2017-12-20
AP2016009223A0 (en) 2016-05-31
PH12016501083A1 (en) 2016-07-25
EP3079660B1 (fr) 2021-03-03
JP2016539991A (ja) 2016-12-22
SV2016005214A (es) 2016-11-21
KR101808977B1 (ko) 2017-12-13
EP3079660A1 (fr) 2016-10-19
CN105979930B (zh) 2019-11-19
WO2015086491A1 (fr) 2015-06-18
EA201691193A1 (ru) 2016-09-30
SG11201604660VA (en) 2016-07-28
AU2014363724B2 (en) 2017-02-23
CR20160261A (es) 2016-08-16
BR112016013325A2 (fr) 2017-08-08
HK1224208A1 (zh) 2017-08-18
CN105979930A (zh) 2016-09-28
PE20160680A1 (es) 2016-07-31
AU2014363724A1 (en) 2016-05-26
EA031802B1 (ru) 2019-02-28
MD20160079A2 (ro) 2016-10-31
US10413504B2 (en) 2019-09-17
KR20160095110A (ko) 2016-08-10

Similar Documents

Publication Publication Date Title
PH12016501083A1 (en) Drug delivery system
BR112012027442B1 (pt) sistema de distribuição de solução iv para distribuição intravenosa de uma solução perigosa e método para fabricação de um dispositivo de filtro de droga perigosa para uso em combinação com um sistema de distribuição intravenosa
WO2009105432A3 (fr) Dispositifs et procédés pour l'administration d'un agent thérapeutique à travers une pneumostomie
BR112012027441A2 (pt) sistemas e métodos para fornecimento de um conjunto iv de droga perigosa de ventilação fechada
ATE489048T1 (de) Vorrichtung für kombinierte behandlung
MX381766B (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia.
EA201001244A1 (ru) Система доставки лекарственного средства со стабилизирующим эффектом
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
MX2021001867A (es) Administracion y monitoreo de oxidio nitrico en fluidos ex vivo.
BRPI0714399B8 (pt) composição farmacêutica líquida oral
EP2589379A4 (fr) Système transdermique d'administration de médicament contenant du donépézil
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
EA201000747A1 (ru) Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки
EP2004172A4 (fr) Méthodes d'administration de médicaments, structures et compositions utilisées dans le système nasolacrymal
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
UY31975A (es) Sistema y administración transdérmica de estrógeno
MX2021003633A (es) Dispositivo de depósito biodegradable subcutáneo.
MX2021011295A (es) Sistemas y metodos para suministrar agentes activos.
WO2009067699A3 (fr) Procédés pour dispenser un système de soin pour un régime à base de médicament de type oxazaphosphorine
DE60125417D1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
WO2009107136A3 (fr) Dispositif, système et méthode d’administration d’un médicament
PH12018501693A1 (en) Perfusion system
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
CL2015001574A1 (es) Terapia combinada para el cancer